Literature DB >> 24688760

Gabapentin pharmacotherapy for antipsychotic-induced akathisia: single-patient experiment and case report.

Maria A Sullivan1, Robert Wilbur2.   

Abstract

This clinical study reports upon the efficacy of gabapentin (Neurontin) for treating severe akathisia (3 on the Barnes Akathisia Rating Scale) in two patients receiving quetiapine (Seroquel), one of whom also received olanzapine (Zyprexa) for a short period. The first patient participated in an open-label experiment in which the bedtime dose of gabapentin was discontinued three times at intervals 1 week apart, resulting in severe akathisia which was quickly terminated by taking his usual 1200 mg gabapentin dose. This patient was also taking high doses of two benzodiazepines and a beta blocker, without therapeutic effect upon his akathisia; only gabapentin was efficacious. The second case is a report of a woman taking a high dose of quetiapine for anxiety who experienced severe akathisia which was relieved by taking 1200 mg of gabapentin. Possible mechanisms of action of gabapentin are discussed. Particular attention is drawn to the difference between neuroleptic-induced akathisia and the neurological condition of restless legs syndrome.

Entities:  

Keywords:  Barnes Akathisia Rating Scale; akathisia; antipsychotics; clonazepam; diazepam; gabapentin; neuroleptics; olanzapine; quetiapine; restless legs syndrome (RLS); timolol maleate

Year:  2014        PMID: 24688760      PMCID: PMC3952486          DOI: 10.1177/2045125314525433

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  8 in total

1.  Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia.

Authors:  Gerald Pfeffer; Guy Chouinard; Howard C Margolese
Journal:  Int Clin Psychopharmacol       Date:  2005-05       Impact factor: 1.659

2.  Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis.

Authors:  Cagla Eroglu; Nicola J Allen; Michael W Susman; Nancy A O'Rourke; Chan Young Park; Engin Ozkan; Chandrani Chakraborty; Sara B Mulinyawe; Douglas S Annis; Andrew D Huberman; Eric M Green; Jack Lawler; Ricardo Dolmetsch; K Christopher Garcia; Stephen J Smith; Z David Luo; Arnon Rosenthal; Deane F Mosher; Ben A Barres
Journal:  Cell       Date:  2009-10-08       Impact factor: 41.582

3.  The therapeutic use of diazepam for akathisia.

Authors:  P T Donlon
Journal:  Psychosomatics       Date:  1973 Jul-Aug       Impact factor: 2.386

4.  Propranolol for akathisia.

Authors:  R Wilbur; A V Kulik
Journal:  Lancet       Date:  1983-10-15       Impact factor: 79.321

5.  Akathisia induced by gabapentin withdrawal.

Authors:  Sharon See; Erin Hendriks; Leslie Hsiung
Journal:  Ann Pharmacother       Date:  2011-06-07       Impact factor: 3.154

6.  Placebo-controlled study of gabapentin treatment of panic disorder.

Authors:  A C Pande; M H Pollack; J Crockatt; M Greiner; G Chouinard; R B Lydiard; C B Taylor; S R Dager; T Shiovitz
Journal:  J Clin Psychopharmacol       Date:  2000-08       Impact factor: 3.153

7.  Treatment effects of gabapentin for primary insomnia.

Authors:  Hsiao-Sui Lo; Chien-Ming Yang; Helen G Lo; Chien-Ying Lee; Hua Ting; Bor-Show Tzang
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

8.  Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin.

Authors:  Jan Hendrich; Alexandra Tran Van Minh; Fay Heblich; Manuela Nieto-Rostro; Katrin Watschinger; Jörg Striessnig; Jack Wratten; Anthony Davies; Annette C Dolphin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-25       Impact factor: 11.205

  8 in total
  3 in total

Review 1.  Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.

Authors:  Haitham Salem; Caesa Nagpal; Teresa Pigott; Antonio Lucio Teixeira
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

2.  Successful Management of Clozapine-induced Akathisia with Gabapentin Enacarbil: A Case Report.

Authors:  Masahiro Takeshima; Hiroyasu Ishikawa; Yuka Kikuchi; Takashi Kanbayashi; Tetsuo Shimizu
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-08-31       Impact factor: 2.582

3.  Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study.

Authors:  Masahiro Takeshima; Hiroyasu Ishikawa; Takashi Kanbayashi; Tetsuo Shimizu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-22       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.